Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renal stenting heads to MedCAC

This article was originally published in The Gray Sheet

Executive Summary

CMS will convene its Medicare Evidence Development Advisory Committee July 18 to reconsider coverage for renal artery angioplasty and stenting. The agency opened the national coverage decision in February in response to a comparative effectiveness review from the Agency for Healthcare Research & Quality that questions the evidence in support of stenting (1"The Gray Sheet" March 5, 2007, p. 8). AHRQ is updating its review as part of the coverage decision process. The MedCAC meeting extends CMS' decision timeline, with a proposed coverage policy for the procedure expected Nov. 26 and a final decision due Feb. 23...
Advertisement

Related Content

Renal Stenting Coverage Reconsidered: AHRQ Comparative Analysis Effect
Renal Stenting Coverage Reconsidered: AHRQ Comparative Analysis Effect
Advertisement
UsernamePublicRestriction

Register

MT024801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel